Everything below concerns Dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Enzyme kinetics is the scientific study of chemical reactions caused by enzyme catalysis, and a subfield of biochemistry. It is concerned with the reaction rate of chemical reactions, their effects, and the varying conditions that cause the reactions. Studying an enzyme's kinetics in this way can reveal the catalytic reaction mechanism of this enzyme, its role in metabolism, how its activity is controlled, and how a drug or a modifier (inhibitor or activator) might affect the rate. An enzyme, often written "E" in reactions, is a protein molecule that serves as a biological catalyst to facilitate and accelerate a chemical reaction in a cell or other biological environment. It does this through binding of one or more other molecules, its substrate (S), which the enzyme acts upon to form the desired product. The substrate binds to the active site of the enzyme to produce an enzyme-substrate complex (ES), and is transformed into an enzyme-product complex (EP) and from there to the product or products (P), via a transition state (ES*). That series of steps is known as the mechanism:
In insects, the word trachea describes a different organ than in vertebrates. Insects have an open respiratory system made up of spiracles, deep airways (tracheae) and tracheoles to conduct air directly to and from metabolic tissues. The distribution of spiracles can vary greatly among the many orders of insects, but in general each body segment can have only one pair of spiracles, each of which connects to an air cavity called atrium and has a relatively large tracheal tube behind it. The tracheae are invaginations of the cuticular exoskeleton that branch (anastomose) throughout the body with diameters from only a few micrometres up to 0.8 mm. Diffusion of oxygen and carbon dioxide takes place across the walls of the smallest tubes, called tracheoles, which penetrate tissues and even indent individual cells. Gas may be conducted through the respiratory system by means of active ventilation or passive diffusion. Unlike vertebrates, insects do not generally carry oxygen in their hemolymph. This is one of the factors that may limit their size. A tracheal tube may contain ridge-like circumferential rings of taenidia in various geometries such as loops or helices. Taenidia provide strength and flexibility to the trachea. In the head, thorax, or abdomen, tracheae may also be connected to air sacs. Many insects, such as grasshoppers and bees, which actively pump the air sacs in their abdomen, are able to control the flow of air through their body.
The second approach utilizes diethyl carbonate in the presence of a strong base to give α-phenylcyanoacetic ester. Alkylation of this ester using ethyl bromide proceeds via a nitrile anion intermediate to give the α-phenyl-α-ethylcyanoacetic ester. This product is then further converted into the 4-iminoderivative upon condensation with urea. Finally acidic hydrolysis of the resulting product gives phenobarbital.
Sources: en.wikipedia.org
All ordinary matter is made up of combinations of chemical elements, each with its own atomic number, indicating the number of protons in the atomic nucleus. Additionally, elements may exist in different isotopes, with each isotope of an element differing in the number of neutrons in the nucleus. A particular isotope of a particular element is called a nuclide. Some nuclides are inherently unstable. That is, at some point in time, an atom of such a nuclide will undergo radioactive decay and spontaneously transform into a different nuclide. This transformation may be accomplished in a number of different ways, including alpha decay (emission of alpha particles) and beta decay (electron emission, positron emission, or electron capture). Another possibility is spontaneous fission into two or more nuclides. While the moment in time at which a particular nucleus decays is unpredictable, a collection of atoms of a radioactive nuclide decays exponentially at a rate described by a parameter known as the half-life, usually given in units of years when discussing dating techniques. After one half-life has elapsed, one half of the atoms of the nuclide in question will have decayed into a "daughter" nuclide or decay product. In many cases, the daughter nuclide itself is radioactive, resulting in a decay chain, eventually ending with the formation of a stable (nonradioactive) daughter nuclide; each step in such a chain is characterized by a distinct half-life.
=== Given name === Reta Beebe (born 1936), American astronomer, author and popularizer of astronomy Reta Cowley (1910–2004), Canadian painter Reta Jo Lewis (born 1953), American Director of Congressional Affairs, an attorney, diplomat Reta Mays (born 1975), American serial killer Reta Shaw (1912–1982), American character actress Reta Trotman (born 1989), New Zealand racing cyclist
A 2016 review of the cardiovascular toxicity of nicotine concluded, "Based on current knowledge, we believe that the cardiovascular risks of nicotine from e-cigarette use in people without cardiovascular disease are quite low. We have concerns that nicotine from e-cigarettes could pose some risk for users with cardiovascular disease." A 2018 Cochrane review found that, in rare cases, nicotine replacement therapy can cause non-ischemic chest pain (i.e., chest pain that is unrelated to a heart attack) and heart palpitations, but does not increase the incidence of serious cardiac adverse events (i.e., myocardial infarction, stroke, and cardiac death) relative to controls.
==== Heart ==== In 2012, stem cells were studied in people with severe heart disease. The work by Bodo-Eckehard Strauer was discredited by identifying hundreds of factual contradictions. Among several clinical trials reporting that adult stem cell therapy is safe and effective, actual evidence of benefit has been reported from only a few studies. Some preliminary clinical trials achieved only modest improvements in heart function following the use of bone marrow stem cell therapy. Stem-cell therapy for the treatment of myocardial infarction usually makes use of autologous bone marrow stem cells, but other types of adult stem cells may be used, such as adipose-derived stem cells. Possible mechanisms of recovery include:Generation of heart muscle cells, Stimulating growth of new blood vessels to repopulate damaged heart tissue and secretion of growth factors.
Sources: en.wikipedia.org
Ukraine's long-term prosperity and security Regional peace and stability in the Middle East Cooperation to increase security and resilience across the Indo-Pacific Building stability and resilience in Haiti and Venezuela Supporting lasting peace in Sudan and the Democratic Republic of the Congo Strengthening sanctions and countering hybrid warfare and sabotage
These clotting mediators also provide a structural staging framework at the inflammatory tissue site in the form of a fibrin lattice – as would construction scaffolding at a construction site – for the purpose of aiding phagocytic debridement and wound repair later on. Some of the exuded tissue fluid is also funneled by lymphatics to the regional lymph nodes, flushing bacteria along to start the recognition and attack phase of the adaptive immune system.
== Structure == Retinal dehydrogenase is a tetramer of identical units, consisting of a dimer of dimers. Retinal dehydrogenase monomers are composed of three domains: a nucleotide-binding domain, a tetramerization domain, and a catalytic domain. The dimer can be pictured as an "X" with the dimers forming upper and lower halves that cross over each other. Interestingly, the nucleotide-binding domain of retinal dehydrogenase contains 5 instead of the usual 6 β-strands in the Rossman fold. This appears to be conserved across many aldehyde dehydrogenases. The tetramerization domains lie equatorially along the "X" and the nucleotide binding regions appear on the tips of the "X". Nearby the tetramerization domain lies a 12 Å deep tunnel that gives the substrate access to the key catalytic regions. Residues near the C-terminal end of the catalytic domain have been found to impart specificity in other aldehyde dehydrogenases. Common to many aldehyde dehydrogenases is a catalytic cysteine, which was found to be present in ALDH1A2 (aka RALDH2), one of the retinal dehydrogenase for which the structure has been solved.
== Process == There are a few methods in which the fusion protein can be introduced into the host cells. If the host is yeast, then one of the methods may be the use of plasmids that will eventually translate the fusion protein within the host. Whichever method that is being used, it is preferable to maintain expression of the fusion protein as close as possible to its natural level. Once the fusion protein is translated within the host, it will interact with other proteins, ideally in a manner unaffected by the TAP tag. Subsequently, the tagged protein (with its binding partners) is retrieved using an affinity selection process. The first type of bead added is coated with Immunoglobulin G, which binds to the TAP tag's outermost end. The beads, with the proteins of interest, are separated from the lysate via centrifugation. The proteins are then released from the beads by an enzyme (TEV protease) which breaks the tag at the TEV cleavage site in the middle. After this first purification step, a second type of bead (coated with calmodulin) is added to the released proteins which binds reversibly to the remaining piece of the TAP tag still on the proteins. The beads are again separated by centrifugation, further removing contaminants as well as the TEV protease. Finally, the beads are released by EGTA, leaving behind the native eluate containing only the protein of interest, its bound protein partners and the remaining CBP piece of the TAP tag. The native eluate can then be analyzed using gel electrophoresis and mass spectrometry to identify the protein's binding partners.
The a2 Corporation claims that milk containing A1 proteins is harmful, but a 2009 European Food Safety Authority (EFSA) review of scientific literature found there was insufficient evidence to prove that bioactive peptides in standard milk have a negative effect on health. A1 and A2 beta-casein are genetic variants of the beta-casein milk protein that differ by one amino acid. The A1 beta-casein type is the most common type found in cow's milk in Europe (excluding France), the US, Australia and New Zealand. A genetic test, developed by the A2 Milk Company, determines whether a cow produces the A2 or A1 type protein in its milk. The test allows the a2 Milk Company to license milk producers once proven their cows produce only A2 beta-casein protein in their milk, to the exclusion of the A1 beta-casein protein type.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.